ESMO 2019 | PAOLA-1 Phase 3 data: olaparib plus bevacizumab maintenance for advanced ovarian cancer

Isabelle Ray-Coquard

Isabelle Ray-Coquard, MD, PhD, of Léon Bérard Center, Lyon, France, discusses the phase 3 PAOLA-1/ENGOT-ov25 trial (NCT02477644) at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain. Prof. Ray-Coquard highlights data from the trial regarding the use of olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed advanced ovarian cancer treated with platinum- based chemotherapy plus bevacizumab. Susana Banerjee, MBBS, PhD, FRCP, of the Royal Marsden NHS Foundation Trust, London, UK, then provides an insightful commentary.

Share this video